ABV + tenofovir disoproxil fumarate + lopinavir + ritonavir

This is a combination antiretroviral therapy consisting of ABV (likely intended as abacavir, but the abbreviation "ABV" is not standard and may be incorrect), tenofovir disoproxil fumarate, lopinavir, and ritonavir. These agents are used together to treat human immunodeficiency virus (HIV) infection. Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, thereby blocking viral replication[6][9]. Lopinavir and ritonavir are protease inhibitors; ritonavir acts primarily as a pharmacokinetic booster for lopinavir by inhibiting its metabolism via CYP3A4[5][7][8]. This combination targets multiple steps in the HIV life cycle to reduce viral load and delay disease progression. Such regimens are typically used in patients with HIV-1 infection who require multi-drug therapy for effective viral suppression.